Compare Best Buy Co Inc (BBY) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Crispr Therapeutics AG — how do they compare? Best Buy Co Inc trades at $82.89 (market cap $17.55B), while Crispr Therapeutics AG trades at $53.6 (market cap $5.23B). The key difference: Best Buy Co Inc is far larger — about 3.4× Crispr Therapeutics AG's market cap, and Best Buy Co Inc pays a 4.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BBY | CRSP | |
|---|---|---|
Market Cap | $17.55B | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $76.78 |
52-Week Low | $55.52 | $44.34 |
Enterprise Value | $19.93B | $3.65B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.
Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
